Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

181 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment.
Caputo E, Miceli R, Motti ML, Taté R, Fratangelo F, Botti G, Mozzillo N, Carriero MV, Cavalcanti E, Palmieri G, Ciliberto G, Pirozzi G, Ascierto PA. Caputo E, et al. Among authors: cavalcanti e. J Transl Med. 2014 Jul 31;12:216. doi: 10.1186/s12967-014-0216-z. J Transl Med. 2014. PMID: 25074438 Free PMC article.
Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma.
Daponte A, Signoriello S, Maiorino L, Massidda B, Simeone E, Grimaldi AM, Caracò C, Palmieri G, Cossu A, Botti G, Petrillo A, Lastoria S, Cavalcanti E, Aprea P, Mozzillo N, Gallo C, Comella G, Ascierto PA; Southern Italy Cooperative Oncology Group (SICOG). Daponte A, et al. Among authors: cavalcanti e. J Transl Med. 2013 Feb 13;11:38. doi: 10.1186/1479-5876-11-38. J Transl Med. 2013. PMID: 23402397 Free PMC article. Clinical Trial.
Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma.
Simeone E, Gentilcore G, Giannarelli D, Grimaldi AM, Caracò C, Curvietto M, Esposito A, Paone M, Palla M, Cavalcanti E, Sandomenico F, Petrillo A, Botti G, Fulciniti F, Palmieri G, Queirolo P, Marchetti P, Ferraresi V, Rinaldi G, Pistillo MP, Ciliberto G, Mozzillo N, Ascierto PA. Simeone E, et al. Among authors: cavalcanti e. Cancer Immunol Immunother. 2014 Jul;63(7):675-83. doi: 10.1007/s00262-014-1545-8. Epub 2014 Apr 3. Cancer Immunol Immunother. 2014. PMID: 24695951
Ran signaling in melanoma: implications for the development of alternative therapeutic strategies.
Caputo E, Wang E, Valentino A, Crispi S, De Giorgi V, Fico A, Ficili B, Capone M, Anniciello A, Cavalcanti E, Botti G, Mozzillo N, Ascierto PA, Marincola FM, Travali S. Caputo E, et al. Among authors: cavalcanti e. Cancer Lett. 2015 Feb 1;357(1):286-296. doi: 10.1016/j.canlet.2014.11.033. Epub 2014 Nov 20. Cancer Lett. 2015. PMID: 25444926 Free PMC article.
c-Myc modulation: a key role in melanoma drug response.
Fico A, Alfano D, Valentino A, Vasta V, Cavalcanti E, Travali S, Patriarca EJ, Caputo E. Fico A, et al. Among authors: cavalcanti e. Cancer Biol Ther. 2015;16(9):1375-86. doi: 10.1080/15384047.2015.1030546. Epub 2015 Apr 2. Cancer Biol Ther. 2015. PMID: 25835050 Free PMC article.
Phenotype characterization of human melanoma cells resistant to dabrafenib.
Cordaro FG, De Presbiteris AL, Camerlingo R, Mozzillo N, Pirozzi G, Cavalcanti E, Manca A, Palmieri G, Cossu A, Ciliberto G, Ascierto PA, Travali S, Patriarca EJ, Caputo E. Cordaro FG, et al. Among authors: cavalcanti e. Oncol Rep. 2017 Nov;38(5):2741-2751. doi: 10.3892/or.2017.5963. Epub 2017 Sep 18. Oncol Rep. 2017. PMID: 29048639 Free PMC article.
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
Capone M, Giannarelli D, Mallardo D, Madonna G, Festino L, Grimaldi AM, Vanella V, Simeone E, Paone M, Palmieri G, Cavalcanti E, Caracò C, Ascierto PA. Capone M, et al. Among authors: cavalcanti e. J Immunother Cancer. 2018 Jul 16;6(1):74. doi: 10.1186/s40425-018-0383-1. J Immunother Cancer. 2018. PMID: 30012216 Free PMC article.
Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients.
Capone M, Fratangelo F, Giannarelli D, Sorrentino C, Turiello R, Zanotta S, Galati D, Madonna G, Tuffanelli M, Scarpato L, Grimaldi AM, Esposito A, Azzaro R, Pinto A, Cavalcanti E, Pinto A, Morello S, Ascierto PA. Capone M, et al. Among authors: cavalcanti e. J Transl Med. 2020 Mar 11;18(1):121. doi: 10.1186/s12967-020-02285-0. J Transl Med. 2020. PMID: 32160899 Free PMC article.
Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis.
Isgrò MA, Vitale MG, Celentano E, Nocerino F, Porciello G, Curvietto M, Mallardo D, Montagnese C, Russo L, Zanaletti N, Avallone A, Pensabene M, De Laurentiis M, Centonze S, Pignata S, Cannella L, Morabito A, Caponigro F, Botti G, Masucci GV, Giannarelli D, Cavalcanti E, Ascierto PA. Isgrò MA, et al. Among authors: cavalcanti e. J Transl Med. 2021 Mar 31;19(1):132. doi: 10.1186/s12967-021-02798-2. J Transl Med. 2021. PMID: 33789686 Free PMC article.
181 results